Skip to main content
. 2021 Sep 12;8(6):5282–5292. doi: 10.1002/ehf2.13614

Figure 3.

Figure 3

Survival analyses of long‐term clinical outcomes of patients with cardiac sarcoidosis categorized by sIL‐2R. (A) Composite of advanced atrioventricular block, VT/VF, heart failure hospitalization, and all‐cause death. (B) All‐cause death. (C) VT/VF. (D) Heart failure hospitalization. sIL‐2R, soluble interleukin 2 receptor; VF, ventricular fibrillation; VT, ventricular tachycardia